T14 Peptide Biomarker for Non-Invasive Braak Staging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Alzheimer's disease are inadequate, as there is no single test for diagnosis or prognosis of cognitive decline, and existing diagnostic tools like PET scans are costly, invasive, and difficult to interpret, with Braak staging only possible post-mortem.
Innovation Solution
The use of a novel biomarker, T14 peptide derived from acetylcholinesterase, which correlates with Braak stages, allowing for non-invasive determination of Braak staging and the need for PET scans through blood or CSF analysis, enabling precise diagnosis and treatment planning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PET scans are used to diagnose Alzheimer's disease, then diagnostic accuracy is improved, but cost and invasiveness increase
Solution Approach 1:
The patent replaces expensive, invasive PET scans with a cheap, non-invasive blood test that measures T14 peptide levels. The blood test serves as a disposable, low-cost alternative to the expensive imaging procedure while maintaining diagnostic utility for determining Braak stage and amyloid positivity.
Solution Approach 2:
The T14 peptide serves as an intermediary biomarker that correlates with both Braak stage and amyloid status. Instead of directly performing PET scans or post-mortem examinations, the patent uses T14 levels in blood as an indirect measure to infer the underlying pathological state, enabling diagnosis without direct brain imaging or autopsy.
2Measurement precision
If post-mortem brain examination is performed for Braak staging, then staging accuracy is improved, but applicability to living patients is lost
Solution Approach 1:
The T14 peptide acts as a biomarker intermediary that reflects the pathological state associated with Braak staging. By measuring T14 levels in blood from living patients and comparing them to reference values from post-mortem specimens, the patent translates post-mortem staging accuracy into a living patient diagnostic tool.
Solution Approach 2:
The patent creates a surrogate measurement system where blood T14 levels serve as a copy or proxy for the actual Braak stage determined by post-mortem examination. This copying approach allows the staging information to be obtained from living patients without requiring actual brain examination.
3Reliability
If PET scans are performed on all suspected cases, then diagnostic coverage is improved, but resource utilization and cost efficiency worsen
Solution Approach 1:
The patent implements a two-stage diagnostic approach where the inexpensive T14 blood test is performed first as a preliminary screening tool. Only patients with abnormal T14 results or high clinical suspicion proceed to PET scanning, thereby avoiding unnecessary resource expenditure on patients who do not require advanced imaging.
Solution Approach 2:
Instead of applying the expensive PET scan to all cases (excessive action), the patent applies it only partially to those who meet specific criteria based on T14 levels and clinical presentation. This partial application of the expensive test optimizes resource utilization while maintaining diagnostic reliability for those who need it.
Data Source
AI summary
The invention relates to biomarkers, and particularly, although not exclusively, to biomarkers for neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease or Motor Neurone disease. The invention especially relates to novel biomarkers for facilitating Braak staging for classifying the degree of pathology in Alzheimer's disease in living patients, and determining the need or otherwise of Positron Emission Topography (PET) scanning for detecting the presence of beta amyloid in the brain. The invention further provides diagnostic and prognostic methods and kits for neurodegenerative disorders, and for Braak staging and determining the need for conducting a PET scan on a subject suspected of suffering from Alzheimer's disease.